Log In Get Started
Press Releases April 23, 2026 08:00 AM

Belite Bio to Participate in Four Upcoming Investor Conferences

Belite Bio to Present at Four Upcoming Investor Conferences in April and May 2026

By Marcus Reed BLTE
Belite Bio to Participate in Four Upcoming Investor Conferences
BLTE

Belite Bio, a clinical-stage biopharmaceutical company focused on treatments for degenerative retinal diseases, announced participation in four upcoming investor conferences between April and May 2026. The company will provide presentations and fireside chats detailing progress and prospects for its lead drug candidate, tinlarebant, which is currently in Phase 2/3 and Phase 3 clinical trials for Stargardt disease type 1 and geographic atrophy in dry AMD.

Key Points

  • Belite Bio will participate in four investor conferences including Deutsche Bank ADR, BofA Securities Healthcare, H.C. Wainwright BioConnect Nasdaq, and Stifel Virtual Ophthalmology Forum.
  • The company’s lead candidate, tinlarebant, is an oral therapy targeting retinal diseases STGD1 and GA, currently in mid-to-late stage clinical trials.
  • The company offers webcasts and archived replays for investors to access presentations, enhancing transparency and investor communication.

SAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in four upcoming investor conferences. Details of the presentations are as follows:  

  • Deutsche Bank American Depositary Receipt Virtual Investor Conference (Virtual)
    • April 28, 2026, at 9:00 am ET, corporate presentation
  • BofA Securities 2026 Health Care Conference (Las Vegas, NV)
    • May 13, 2026, at 3:40 pm PT, fireside chat
  • H.C. Wainwright 4th Annual BioConnect Nasdaq Investor Conference (New York, NY)
    • May 19, 2026, at 5:00 pm ET, fireside chat
  • Stifel 2026 Virtual Ophthalmology Forum (Virtual)
    • May 26, 2026, at 12:30 pm ET, fireside chat

Webcast Link Instructions
Webcasts of the presentations can be accessed under "Events" in the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events. The replays will be archived for 90 days following the presentation date.

About Belite Bio
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio’s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent STGD1 subjects, and the drug is currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent STGD1 subjects and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook, or visit us at www.belitebio.com.

Media and Investor Relations Contacts:
Jennifer Wu / [email protected]
Argot Partners / [email protected] 


Risks

  • Clinical trial outcomes are uncertain; Phase 2/3 and Phase 3 studies may not yield positive results, impacting drug approval chances and company valuation.
  • Market adoption of tinlarebant depends on regulatory approvals and competitive landscape in ophthalmology therapeutics.
  • Participation in investor conferences does not guarantee increased investment or market enthusiasm, and stock response may remain muted if no significant new data are presented.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026